 | A major contributor to this article appears to have a close connection with its subject. (September 2022) |
 | |
| Company type | Aktieselskab |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 14 August 1915 |
| Founder | Hans Lundbeck |
| Headquarters | Copenhagen, Denmark |
Key people | |
| Website | lundbeck |
H. Lundbeck A/S, commonly referred to as Lundbeck, is a Danish international pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at brain diseases, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease and migraine.[2]
Headquartered in Copenhagen, Denmark, Lundbeck has approximately 5,600 employees[3] in more than 50 countries, and their products are registered in more than 100 countries. They have production facilities in Denmark, France and Italy and their research centers are based in Denmark and the US.[2]
Lundbeck is listed on the Copenhagen Stock Exchange (CSE).[4]
Lundbeck is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
- ^ "Lundbeck replaces retiring CEO Dunsire with UCB exec after breaking sales record". 27 June 2023. Retrieved 2023-06-27.
- ^ a b "Facts and background". lundbeck.com. Retrieved 2021-04-07.
- ^ "Wayback Machine" (PDF). 2021-06-11. Archived from the original (PDF) on 2021-06-11. Retrieved 2023-01-25.
- ^ "Shareholder Composition and Dividends".